191 related articles for article (PubMed ID: 9259428)
41. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
42. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
43. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
Fleming E; Lien H; Ma CT; McGuire TG
J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
[TBL] [Abstract][Full Text] [Related]
44. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Haglund U; Svarvar P
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():51-6. PubMed ID: 11276803
[TBL] [Abstract][Full Text] [Related]
45. The costs of rheumatoid arthritis.
Allaire SH; Prashker MJ; Meenan RF
Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
[TBL] [Abstract][Full Text] [Related]
46. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.
Lajas C; Abasolo L; Bellajdel B; Hernández-García C; Carmona L; Vargas E; Lázaro P; Jover JA
Arthritis Rheum; 2003 Feb; 49(1):64-70. PubMed ID: 12579595
[TBL] [Abstract][Full Text] [Related]
47. [Epidemiology, resource use and costs of rheumatoid arthritis in Argentina].
Secco A; Alfie V; Espinola N; Bardach A
Rev Peru Med Exp Salud Publica; 2020 Dec; 37(3):532-540. PubMed ID: 33295558
[TBL] [Abstract][Full Text] [Related]
48. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
[TBL] [Abstract][Full Text] [Related]
49. Costs and outcomes in rheumatoid arthritis and osteoarthritis.
Liang MH; Larson M; Thompson M; Eaton H; McNamara E; Katz R; Taylor J
Arthritis Rheum; 1984 May; 27(5):522-9. PubMed ID: 6721884
[TBL] [Abstract][Full Text] [Related]
50. Increased frequency and costs of ambulatory medical care utilization prior to the diagnosis of rheumatoid arthritis: a national population-based study.
Lai NS; Tsai TY; Li CY; Koo M; Yu CL; Lu MC
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):371-8. PubMed ID: 23983071
[TBL] [Abstract][Full Text] [Related]
51. Modeling the lifetime costs of rheumatoid arthritis.
Gabriel SE; Crowson CS; Luthra HS; Wagner JL; O'Fallon WM
J Rheumatol; 1999 Jun; 26(6):1269-74. PubMed ID: 10381041
[TBL] [Abstract][Full Text] [Related]
52. Outcome of knee revisions for osteoarthritis and inflammatory arthritis with postero-stabilized arthroplasties: a mean ten-year follow-up with 90 knee revisions.
Hernigou P; Dubory A; Potage D; Roubineau F; Flouzat-Lachaniette CH
Int Orthop; 2017 Apr; 41(4):757-763. PubMed ID: 27787574
[TBL] [Abstract][Full Text] [Related]
53. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective.
Lee DW; Meyer JW; Clouse J
Value Health; 2001; 4(4):329-34. PubMed ID: 11705300
[TBL] [Abstract][Full Text] [Related]
54. Direct and indirect costs attributable to osteoarthritis in active subjects.
Rabenda V; Manette C; Lemmens R; Mariani AM; Struvay N; Reginster JY
J Rheumatol; 2006 Jun; 33(6):1152-8. PubMed ID: 16755664
[TBL] [Abstract][Full Text] [Related]
55. Medical services and associated costs vary widely among surgeons treating patients with hand osteoarthritis.
Becker SJ; Teunis T; Blauth J; Kortlever JT; Dyer GS; Ring D
Clin Orthop Relat Res; 2015 Mar; 473(3):1111-7. PubMed ID: 25171936
[TBL] [Abstract][Full Text] [Related]
56. [Costs of ambulatory care for RA patients in Germany].
Mittendorf T; Merkesdal S; Zeidler H; Graf von der Schulenburg JM; Ruof J
Med Klin (Munich); 2005 May; 100(5):255-61. PubMed ID: 15902379
[TBL] [Abstract][Full Text] [Related]
57. Estimating the health-care usage associated with osteoarthritis and rheumatoid arthritis in an older adult population in Ireland.
Doherty E; O'Neill C
J Public Health (Oxf); 2014 Sep; 36(3):504-10. PubMed ID: 24097191
[TBL] [Abstract][Full Text] [Related]
58. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
59. Primary care physician compensation method in medical groups: does it influence the use and cost of health services for enrollees in managed care organizations?
Conrad DA; Maynard C; Cheadle A; Ramsey S; Marcus-Smith M; Kirz H; Madden CA; Martin D; Perrin EB; Wickizer T; Zierler B; Ross A; Noren J; Liang SY
JAMA; 1998 Mar; 279(11):853-8. PubMed ID: 9516000
[TBL] [Abstract][Full Text] [Related]
60. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis.
Franke LC; Ament AJ; van de Laar MA; Boonen A; Severens JL
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S118-23. PubMed ID: 19822057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
